Our financial reports are only available in Swedish.
AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
Subscribe to AcuCort's newsletter
Message from the CEO
“AcuCort is entering a new and exciting phase, focusing on the commercialisation of our innovative and patient-friendly oral film Zeqmelit®, for acute and severe allergic reactions, among others.”
Jonas Jönmark, CEO, AcuCort AB
February 24, 2023
We make good drugs better
AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.
Latest videos from AcuCort
Acucort – Stora Aktiedagen Stockholm 15 mars 2023
March 16, 2023 09:45
AcuCort – Bokslutskommuniké 2022
February 24, 2023 10:48